ST. PETERSBURG, Fla., Jan. 16, 2013 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces data from two independent clinical evaluations that indicate favorable results in preventing surgical site infections when using the PICO Negative Pressure Wound Therapy System ("PICO") post-operatively following a Caesarean section.
Jeanette Harris, Infection Preventionist, and Evelyn Hickson, Perinatal Clinical Nurse Specialist from MultiCare Health System in the Tacoma, WA area, conducted a study on outcomes from a new post-operative strategy to manage C-sections introduced in January 2012. Analysis of outcomes using the new strategy showed an 83% reduction in surgical site infections ("SSI"), arriving at a rate of 0.5 percent or six surgical site infections out of a total of 1,200. The average re-admission stay due to post-operative SSI is seven patient days at a cost of roughly $50,000. 
Under MultiCare's protocol, patients were separated into high-risk and low-risk categories through a decision tree. Patients with a body mass index of 35 or greater, or had two or more risk factors, for example diabetes, steroid therapy within 48 hours of surgery, autoimmune diseases, hematological disorders, immune suppression, or others were identified as high-risk. High-risk patients were treated with PICO, while OPSITE Post-Op Visible was used as a low-risk dressing. ACTICOAT antimicrobial barrier dressings were used in both risk groups. Before this, standard practice included the use of conventional post-operative dressings on lowrisk patients, and conventional negative pressure wound therapy for high-risk patients.
"We are committed to innovation that helps reduce the human and economic cost of wounds," said Tom Dugan, President, North America, Advanced Wound Management division, Smith & Nephew. "PICO, OPSITE and ACTICOAT are examples of Smith & Nephew's unique ability to provide a spectrum of wound care options that together give clinicians the flexibility to exercise their best judgment and to develop better ways to serve patients."
A second study presented by Lindsey Bullough and Diane Wilkinson of the Royal Albert Edward Infirmary in Wigan followed a group of 50 patients who were deemed to be at higher risk of contracting an infection post-C-section due to being clinically obese and had their closed surgical incisions treated with a protocol including the PICO Negative Pressure Wound Therapy System. The results showed that there were no infections and zero re-admissions.
"Infections impact not only the mother and her family but also the health service costs in relation to antibiotic use, general practitioner time and additional care," said Diane Wilkinson, Infection Control, Junior Matron at Royal Albert Edward Infirmary.
"I had an emergency C-section and was a bit nervous about my recovery since I had had an infection with my first C-section," said Michelle Mann, a mother of three and a patient who was part of the Wigan evaluation. "For me, PICO was as easy as wearing a belt. It didn't restrict my movements at all and it was easy to remove for showering. I didn't have an infection after this surgery and overall my recovery was much better the second time around."
For more information about the PICO Negative Pressure Wound Therapy System, please visit www.mypico.com or www.possiblewithpico.com or follow the @woundcare Twitter handle for the latest news from the Advanced Wound Management division of Smith & Nephew.
For more information about OPSITE Post-Op Visible please visit www.opsitepostop.com.
For more information about Smith & Nephew, please visit www.smith-nephew.com.
 Jeanette Harris MS, MSM, BS, T/CLS(ASCP), CIC MHS Infection Prevention. "Using a Multi-Faceted Active Change Process and Infection Prevention to Reduce Post Op C-Section Infections." Association for Professionals in Infection Control and Epidemiology 39th Annual Educational Conference & International Meeting. San Antonio, TX.June 4, 2012. Oral presentation.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine, Trauma and Clinical Therapies, Smith & Nephew has almost 11,000 employees and a presence in more than 90 countries. Annual sales in 2011 were nearly $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew